Recipharm

OUR FULL SERVICE OFFERING

YOUR PARTNER FROM DEVELOPMENT TO COMMERCIAL SUPPLY

At Recipharm, we partner with pharmaceutical and biopharmaceutical companies to bring medicines to patients around the world. As a leading contract development and manufacturing organisation (CDMO), we combine scientific expertise, operational excellence and a customer-first mindset to support products throughout their lifecycle, from development and scale-up through to commercial manufacture and supply.

With capabilities spanning oral dosage forms and other small molecule products, sterile drug products, biologics and advanced therapies, we offer a broad range of development and manufacturing services across multiple modalities and dosage forms. Our integrated platforms enable customers to access the technologies, services and support they need today while providing the flexibility to support future growth and evolving programme requirements.

BUILT ON PARTNERSHIP

We believe successful programmes are built on strong partnerships. By working as an extension of our customers' teams, we combine technical expertise, transparent communication and agile decision-making to help reduce complexity, manage risk and accelerate progress. Whether supporting an emerging biotech company or a global pharmaceutical organisation, we are committed to delivering quality, reliability and responsiveness at every stage of the journey.

GLOBAL SCALE, LOCAL AGILITY

With 17 development and manufacturing facilities worldwide, we combine the reach, expertise and security of a global CDMO with the flexibility and personal attention of a trusted local partner. Our network enables customers to access specialised capabilities, reliable supply chains and local market knowledge, while benefiting from the consistency and support of a single global organisation.

COMMITTED TO A SUSTAINABLE FUTURE

We work with our customers to identify opportunities to improve sustainability across product lifecycles and supply chains, while continuously reducing the environmental impact of our own operations. By improving resource efficiency, adopting more responsible practices and collaborating to identify opportunities throughout the product lifecycle, we aim to create lasting value for our customers, employees, communities and future generations.

SOLIDS & OTHERS

DRUG SUBSTANCE	Bengaluru	Leganés	Monheim/ Zwickau	Paderno Dugnano	Pianezza	Queluz/ Odivelas	Uppsala
Small molecule				● ●			
SOLIDS							
Tablets	● ●	●	● ●	●		●	●
Effervescent tablets	● ●	●				●	
Capsules	● ●	●	● ●	●		●	
Coated pellets	●		●				
Granules, powders	● ●	●	● ●			●	
SEMI-SOLIDS							
Suppositories						●	●
Gels, ointments, creams	●					●	
Pre-filled syringes, cartridges							
Terminal sterilisation							
LIQUIDS							
Sprays					●	●	
Aerosols							
Suspensions, emulsions	●				●	●	
Liquids	●				●	●	
SPECIALTY							
High potency		● ●					
Beta-lactam	●						
Controlled drugs	● ●	●	●		●	●	
Analytical specialty lab	●						
PACKAGING							
Blisters	● ●	●	●		●	●	●
Bottles, jars	● ●	●	●			●	●
Tubes	●					●	
Sachets	●		●			●	
Secondary pack pre-filled syringes			●				

● Manufacturing ● Development

GMP LICENSES & ISO							
FDA (US)	●	●	●	●	●	●	●
EU GMP	●	●	●	●	●	●	●
PMDA (JPN)	●	●	●	●		●	●
Clinical trial material (IMP)	●	●	●	●		●	●
Veterinary products				●	●	●	
ISO 13485	●						
ISO 14001	●	●	●	●	●	●	●
ISO 45001/OHSAS 18001	●	●	●	●		●	●

STERILE DELIVERY

FILL & FINISH	Bengaluru	Benslimane	Brescia	Cuxhaven	Kaysersberg	Lenoir	Masate	Wasserburg	Watertown
Vials		●	●	● ●		●	●	● ●	●
Ampoules			●				●		
Pre-filled syringes/cartridges		●				●		● ●	
Lyophilisation in vials				● ●		●	●	●	
Dry powder fill			●						
Beta-lactam			●						
Vaccines		●		● ●	●	●		●	●
Blow-fill-seal					● ●				
Terminal or bulk sterilisation			●	● ●	●	●	●	●	
Parenteral development	●								
INSPECTION & PACKAGING									
Manual		●	●	●	●	●	●	●	●
Semi-automatic		●	●	●	●	●	●	●	
Automatic		●	●		●	●	●	●	
Labeling		●	●	●	●	●	●	●	
Pouching					●				
Packaging incl. serialisation		●	●		●	●	●	●	

● Manufacturing ● Development

GMP LICENSES & ISO									
FDA (US)			●		●	●		●	
EU GMP			●	●	●		●	●	
PMDA (JPN)					●			●	
Clinical trial material (IMP)			●	●	●		●	●	●
Veterinary products			●						
ISO 13485					●				
ISO 14001			●		●		●	●	
ISO 45001/OHSAS 18001			●		●		●	●	

VIRAL

RAW & STARTING MATERIALS	Cuxhaven	Oeiras	Watertown, MA
Plasmid DNA production		●	●
Pre-MVSS rescue from plasmid	●	●	
Proprietary cell line licensing (Cevec, Expres2ion, Advec)	●	●	
Cell bank production (MCB/WCB)	●	●	●
Master virus seed production (MVSS/WVSS)	●	●	

DEVELOPMENT			
Process development (USP, DSP, formulation)	●	●	●
Analytical method establishment (IPC, QC lot release)	●	●	●

MANUFACTURE, FILL & FINISH			
Drug substance (non-GMP/GMP)	●	●	●
- Avian-based production (eggs, chick-embryo fibroblasts)	●		
- Cell culture-based production (primary, continuous cell lines)	●	●	●
Drug product (non-GMP/GMP)	●	●	●
Sterile fill & finish (liquid)	●	●	●
Sterile fill & finish (lyophilisation)	●		

QUALITY CONTROL RELEASE & STABILITY			
In-process control, drug substance & drug product testing	●	●	●
Quality control lot release testing	●	●	●
Control cell generation	●	●	
Assay qualification & validation	●	●	●
Stability studies	●	●	●

NUCLEIC-ACID-BASED

RAW & STARTING MATERIALS			
Plasmid cloning			●
Plasmid DNA production		●	●

DEVELOPMENT			
Process (IVT, DNA digestion, RNA purification)		●	●
Analytical assays		●	●
mRNA encapsulation			●

MANUFACTURE, FILL & FINISH			
Fermentation & plasmid expansion		●	●
Plasmid linearisation, transcription, capping, tailing		●	●
mRNA encapsulation (lipid nanoparticle formulation)			●
Drug product (non-GMP/GMP)		●	●
- Vials		●	●

QUALITY CONTROL RELEASE & STABILITY			
In-process control sample testing		●	●
Quality control release testing		●	●
Assay qualification & validation		●	●
Stability studies		●	●

MICROBIOME/LIVE BIOTHERAPEUTHIC PRODUCTS

RAW & STARTING MATERIALS	Cuxhaven*	Oeiras	Watertown, MA
Strain selection		●	
Colony isolation		●	
Cell bank production (MCB/WCB)	●	●	
Proprietary media		●	

DEVELOPMENT			
Process (USP, DSP, formulation)	●	●	
Analytical assays	●	●	
Analytical method transfer & development	●	●	

MANUFACTURE, FILL & FINISH			
Drug substance (non-GMP/GMP)	●	●	
Drug product (non-GMP/GMP)	●	●	
- Capsules		●	
- Bottles		●	
- Vials	●	●	

QUALITY CONTROL RELEASE & STABILITY			
In-process control, drug substance & drug product testing	●	●	
Quality control release testing	●	●	
Assay qualification & validation	●	●	
Stability studies	●	●	



CONNECTED CAPABILITIES, GLOBAL REACH

Our global development and manufacturing network brings together specialised technologies, services and capabilities across oral dosage forms, sterile drug products, biologics and advanced therapies. With facilities strategically located around the world and products supplied to more than 100 markets, we provide you with access to the capabilities, support and local knowledge you need throughout your development and commercialisation journey, backed by the reach and strength of a global organisation.

STERILE DELIVERY

France
Kaysersberg

Germany
Wasserburg

India
Bengaluru

Italy
Masate
Brescia

Morocco
Benslimane

ADVANCED BIOLOGICS

Germany
Cuxhaven

Portugal
Oeiras

USA
Watertown

SOLIDS & OTHERS

Germany
Monheim
Zwickau

India
Bengaluru

Italy
Paderno Dugnano
Pianezza

Portugal
Odivelas
Queluz

Spain
Leganés

Sweden
Uppsala

ASSOCIATED COMPANIES

New Biologix
Gene therapy
(Switzerland)

Exela Pharma Sciences
Sterile manufacturing
(USA)

SERIOUS ABOUT SUSTAINABILITY

SEPTEMBER 2026